SCHEMBL242330

SCHEMBL242330

O=[N+]([O-])c1cc([C@H]2CC[C@H](c3ccc(Cl)c([N+](=O)[O-])c3)N2c2cc(F)c(N3CCC4(CCCC4)CC3)c(F)c2)ccc1Cl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 1/20 0.36
VCAM1 P19320 4/20 0.35
ABCC9 O60706 1/20 0.35
ABCC8 Q09428 1/20 0.35
KCNJ11 Q14654 1/20 0.35
KCNJ8 Q15842 1/20 0.35
NPBWR1 P48145 1/20 0.35
MCHR1 Q99705 1/20 0.35
KMT2A Q03164 5/20 0.35
MEN1 O00255 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 2/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 4/20 0.34
LMNA P02545 2/20 0.34
RECQL P46063 2/20 0.34
USP2 O75604 1/20 0.34
MCL1 Q07820 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL240239 0.99 NPBWR1 (0.36) FFAR4VCAM1ABCC9ABCC8KCNJ11
SCHEMBL239816 0.96 FFAR4 (0.37) FFAR4VCAM1ABCC9ABCC8KCNJ11
SCHEMBL238875 0.90 KMT2A (0.36) VCAM1ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL240748 0.89 KMT2A (0.35) FFAR4VCAM1ABCC9ABCC8KCNJ11
SCHEMBL238260 0.89 NPBWR1 (0.43) VCAM1NPBWR1MCHR1KMT2AMEN1
SCHEMBL240192 0.87 KMT2A (0.38) VCAM1NPBWR1MCHR1KMT2AMEN1
SCHEMBL240992 0.87 SMN1; SMN2 (0.39) ABCC9ABCC8KCNJ11KCNJ8KMT2A
SCHEMBL240525 0.86 KMT2A (0.39) VCAM1ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL240093 0.85 KMT2A (0.39) VCAM1ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL238444 0.85 KMT2A (0.50) KMT2AMEN1SMN1; SMN2L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 US disclosed
EP-3438106-A1 ANTI-VIRAL COMPOUNDS AbbVie Ireland Unlimited Company (IE) 2019-02-06 EP disclosed
US-20190015402-A1 Anti-Viral Compounds ABBVIE INC. (US) 2019-01-17 US disclosed
US-10039754-B2 Anti-viral compounds ABBVIE INC. (US) 2018-08-07 US disclosed
US-10028937-B2 Anti-viral compounds ABBVIE INC. (US) 2018-07-24 US disclosed
US-20170157105-A1 Anti-Viral Compounds ABBVIE INC. (US) 2017-06-08 US disclosed
US-20170157104-A1 Anti-Viral Compounds ABBVIE INC. (US) 2017-06-08 US disclosed
EP-2678334-B1 ANTI-VIRAL COMPOUNDS ABBVIE BAHAMAS LTD (BS) 2017-03-22 EP disclosed
US-9586978-B2 Anti-viral compounds ABBVIE INC. (US) 2017-03-07 US disclosed
EP-2692346-B1 An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative ABBVIE BAHAMAS LTD (BS) 2015-12-02 EP disclosed
US-8921514-B2 Anti-viral compounds ABBVIE INC. (US) 2014-12-30 US disclosed
EP-2692346-A1 An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative Abbvie Inc. (US) 2014-02-05 EP disclosed
EP-2692726-A1 Anti-viral compounds Abbvie Inc. (US) 2014-02-05 EP disclosed
EP-2678334-A1 ANTI-VIRAL COMPOUNDS Abbvie Inc. (US) 2014-01-01 EP disclosed
EP-2627651-A1 ANTI-VIRAL COMPOUNDS Abbvie Inc. (US) 2013-08-21 EP disclosed
US-20120220562-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2012-08-30 US disclosed
WO-2012116257-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. (US) 2012-08-30 WO disclosed
WO-2012051361-A1 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2012-04-19 WO disclosed
US-20120004196-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2012-01-05 US disclosed
US-20110207699-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10028937-B2 Anti-viral compounds HAVCR2, EIF2AK2, MAVS FFAR4 4564/4885VCAM1 931/4885ABCC9 3180/4885
US-20230285378-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS FFAR4 4564/4885VCAM1 931/4885ABCC9 3180/4885
US-20120220562-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS FFAR4 4564/4885VCAM1 931/4885ABCC9 3180/4885
US-20170157105-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS FFAR4 4564/4885VCAM1 931/4885ABCC9 3180/4885
US-20170157104-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS FFAR4 4564/4885VCAM1 931/4885ABCC9 3180/4885
US-20110207699-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS FFAR4 4564/4885VCAM1 931/4885ABCC9 3180/4885
US-20190015402-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS FFAR4 4564/4885VCAM1 931/4885ABCC9 3180/4885
US-20120004196-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS FFAR4 4564/4885VCAM1 931/4885ABCC9 3180/4885
US-10039754-B2 Anti-viral compounds HAVCR2, EIF2AK2, MAVS FFAR4 4564/4885VCAM1 931/4885ABCC9 3180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.